The effectiveness of Atomoxetine generic in the treatment of ADHD was established in six randomized, double-blind, placebo-controlled studies in children, adolescents, and adults who met the criteria for ADHD, as defined in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). Of these six studies, four were used to assess the drug’s clinical [...]
Atomoxetine generic is supplied as capsules, in strengths of 10, 18, 25, 40, and 60 mg. For children and adolescents weighing up to 70 kg, the recommended initial dose is 0.5 mg/kg. After a minimum of three days, the dose should be increased to a targeted daily dose of 1.2 mg/kg. The targeted daily dose [...]
OVERVIEW In November 2002, the Food and Drug Administration (FDA) approved atomoxetine (Strattera generic, Eli Lilly) for the treatment of Attention-Deficit/Hyper-activity Disorder (ADHD), previously called Attention-Deficit Disorder. Atomoxetine is a potent inhibitor of the pre-synaptic norepinephrine transporter, with minimal affinity for other nor-adrenergic receptors or for other neu-rotransmitter transporters or receptors. Atomoxetine is thought to [...]
